Shanmuga Hospital proposes MD reappointment through February 2032

Shanmuga Hospital Limited has proposed reappointing promoter Dr. Palaniappan Shanmugam Panneerselvam as managing director for five years from February 16, 2027 to February 15, 2032, subject to shareholder approval through a postal ballot. The board approved the proposal on November 12, 2026, following a recommendation from its Nomination and Remuneration Committee.

Why is Shanmuga Hospital reappointing its managing director?

Shanmuga Hospital is seeking shareholder approval to retain Dr. Palaniappan Shanmugam Panneerselvam as managing director for five consecutive years beginning February 16, 2027. The proposed tenure ends on February 15, 2032, and the company has described the action as a reappointment rather than a new appointment.

The board considered and approved the reappointment at its November 12, 2026 meeting, which began at 3:00 pm and ended at 5:10 pm. It also approved the postal-ballot notice and explanatory statement under Section 102 of the Companies Act, 2013, which will be used to seek members’ approval for the proposed term.

The appointment will not take effect unless shareholders approve it through the postal-ballot process. The filing gives the tenure, candidate profile and relationship disclosures, but it does not disclose remuneration, incentives, revised service conditions or voting dates for the ballot.

Who is the proposed managing director of Shanmuga Hospital?

Dr. Palaniappan is one of Shanmuga Hospital’s promoters and one of its first directors, according to the company’s Annexure B disclosure dated November 12, 2026. The company said he has more than 45 years of professional experience in medical and healthcare activities, including general surgery, clinical practice, healthcare administration and hospital management.

His disclosed qualifications include a Bachelor of Medicine and Bachelor of Surgery degree from the University of Madras in 1977 and a Master of Surgery in General Surgery from Madurai Kamaraj University in 1980. He was conferred a Fellowship of the International College of Surgeons in General Surgery in 1988 and has been a life member of the Indian Medical Association since 1991.

Shanmuga Hospital said his experience covers hospital operations, medical services, healthcare infrastructure development and strategic management. Management stated that his experience, professional qualifications and understanding of the healthcare industry support the proposed reappointment and the company’s continued growth and future development.

What family relationships has Shanmuga Hospital disclosed?

Shanmuga Hospital disclosed that Mrs. Panneerselvam Jayalakshmi is Dr. Palaniappan’s wife, Dr. Prabu Sankar Panneerselvam is his son, and Dr. Dhandapani Priyadharshni is his daughter-in-law. These relationships were disclosed in the annexure setting out details of the proposed five-year reappointment through February 15, 2032.

Dr. Prabu Sankar signed Shanmuga Hospital’s standalone financial statements for the half year ended September 30, 2026 as executive director and chief executive officer. The filing identifies separate roles: Dr. Palaniappan is the proposed managing director, while Dr. Prabu Sankar is designated executive director and chief executive officer.

The company reported that it operates in one business segment, meaning segment disclosure was not applicable for the financial period ended September 30, 2026. It also said it had no subsidiary, associate or joint-venture entity for the periods presented, so the disclosed results and leadership proposal concern the standalone company.

How did Shanmuga Hospital perform before the proposed extension?

Shanmuga Hospital reported revenue from operations of Rs 25.35 crore for the half year ended September 30, 2026, up from Rs 24.62 crore in the corresponding half year ended September 30, 2025. Profit after tax increased to Rs 2.69 crore from Rs 2.01 crore, while profit before tax rose to Rs 3.62 crore from Rs 2.70 crore.

For the quarter ended September 30, 2026, revenue from operations was Rs 13.48 crore, compared with Rs 13.14 crore in the September 2025 quarter and Rs 11.87 crore in the June 2026 quarter. Quarterly profit after tax was Rs 1.70 crore, compared with Rs 1.06 crore a year earlier and Rs 98.65 lakh in the preceding quarter.

The half-year increase in profit occurred as cost of consumption declined to Rs 6.12 crore from Rs 8.13 crore and finance costs fell to Rs 16 lakh from Rs 22.86 lakh. Employee-benefit expense increased to Rs 4.49 crore from Rs 3.67 crore, while other expenses rose to Rs 9.62 crore from Rs 8.28 crore; the company reported no exceptional or extraordinary items.

Shanmuga Hospital’s total assets were Rs 54.03 crore at September 30, 2026, compared with Rs 53.06 crore at March 31, 2026. Trade receivables increased to Rs 8.03 crore from Rs 6.86 crore, while cash and cash equivalents rose to Rs 2.47 crore from Rs 1.93 crore.

What will Shanmuga Hospital shareholders vote on next?

Shanmuga Hospital shareholders will vote on the reappointment of Dr. Palaniappan as managing director for the February 16, 2027 to February 15, 2032 period. The company appointed practising company secretary CS Santhanakrishnan Anuradha as scrutinizer for the postal ballot, including remote electronic voting.

The board fixed November 20, 2026 as the cut-off date for determining eligible members who can participate in the postal ballot. The filing does not state the voting window, result date or the approval threshold, leaving the postal-ballot timetable as an unresolved disclosed matter.

Separately, the board declared a first interim dividend of 10 paise per equity share with a face value of Rs 10 for financial year 2026-27. November 20, 2026 is also the dividend record date, and Shanmuga Hospital said payment to eligible shareholders would be made on or before December 11, 2026.

Conclusion

Shanmuga Hospital’s proposal would retain a promoter and first director as managing director through February 15, 2032, subject to a shareholder vote. The proposal comes after the company reported half-year revenue of Rs 25.35 crore and profit after tax of Rs 2.69 crore for the period ended September 30, 2026, compared with Rs 24.62 crore and Rs 2.01 crore respectively a year earlier.

The next event to watch is the postal-ballot process following the November 20, 2026 eligibility cut-off date, including the company’s disclosure of voting dates and results. Shareholders eligible on the same date can also expect the 10-paise interim dividend payment by December 11, 2026, according to the board announcement.